



# SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP- SEC /2019-20/BSE/1107

Dated: 14.02.2020

To,  
Bombay Stock Exchange Ltd,  
Phirojshah Jeejobhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

**Sub: Outcome of the Board Meeting for the FY 2019-20 held on Friday, 14<sup>th</sup> February 2020 with Scrip Code 524703.**

A Meeting of the Board of Directors of the Company duly convened on **Friday, 14<sup>th</sup> February 2020 at 5:00 p.m. and Concluded at 6.40 p.m.** at the Corporate Office of the Company at Sandu Pharmaceuticals Limited, Sandu Nagar, D K Sandu Marg, Chembur 400 001 inter alia, discussed the following business:-

1. It has approved Unaudited Financial Results for the Quarter ended 31<sup>st</sup> December 2019 along with Limited Review Report.
2. It has Re-Appointed M/s Lalit Gawde & Associates, Chartered Accountant, Mumbai engaged with M/s Sandu Pharmaceuticals Limited from past several years for conducting Internal Audit of the functions and activities of the company and Shri. Akhil Pai, Chartered Accountant for Internal Audit of Plant Operations at Pilerne for the Financial Year 2020-21.

You are requested to kindly take the same on record.

Thanking You

Yours Faithfully

**For Sandu Pharmaceuticals Limited**

Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





## Sandu Pharmaceuticals Ltd

STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 31-12-2019

(Rs in Lakhs)

	Particulars	Quarter Ended			Nine Month Ended		Previous Year Ended 31-03-2019
		Quarter Ended 31-12-2019	Corresponding Quarter Ending 30-09-2019	Corresponding Quarter Year Ended 31-12-2018	Nine Month Ended 31-12-2019	Corresponding Nine Month Ended 31-12-2018	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I	Revenue From Operations	1,318.04	1,182.51	1,418.52	3,735.08	3,750.42	4,942.46
II	Other Income	13.05	13.54	12.43	41.01	43.38	57.40
III	Total Income (I+II)	1,331.09	1,196.05	1,430.95	3,776.09	3,793.80	4,999.86
IV	EXPENSES						
	Cost of Materials Consumed	246.11	207.41	203.90	633.15	575.63	854.88
	Purchases of Stock-in-Trade	532.33	252.21	382.95	1,148.53	1,321.11	1,833.24
	Changes in Inventories of Finished Goods, Stock-in -Trade and Work-in-Progress	(80.59)	112.47	231.29	205.14	90.47	(156.89)
	Excise Duty on Sale of Goods						
	Employee Benefits Expense	171.27	181.89	143.82	500.43	469.38	648.98
	Finance costs	7.79	11.67	23.64	33.19	82.10	101.18
	Depreciation and Amortization Expense	13.93	13.86	16.06	41.39	47.90	63.58
	Other Expenses	418.53	381.00	410.95	1,130.13	1,122.48	1,552.86
	Total Expenses (IV)	1,309.37	1,160.50	1,412.61	3,691.95	3,709.07	4,897.83
V	Profit/(Loss) Before Exceptional Items and Tax (I- IV)	21.72	35.55	18.34	84.14	84.73	102.03
VI	Exceptional Items	-	0.44		0.44		0.26
VII	Profit/(Loss) Before Tax (V-VI)	21.72	35.09	18.34	83.70	84.73	101.77
	Tax Expense:						
VIII	(1) Current Tax	5.66	9.12	4.77	21.76	22.03	36.50
	(2) Deferred Tax	0.43	2.72	5.05	6.85	0.70	(1.64)
	(3) Short /Excess Proviison	-	-	-	(14.81)	-	-
IX	Profit (Loss) for the period from Continuing Operations (VII-VIII)	15.65	23.25	8.52	69.90	62.00	66.91
X	Profit/(Loss) for the period (IX+XII)	15.65	23.25	8.52	69.90	62.00	66.91
XI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	3.26	(4.24)	3.50	5.16	0.44	4.97
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.33)	0.92	(0.36)	(0.04)	(0.45)	(1.25)
	B (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss						
XII	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	18.58	19.93	11.66	75.02	61.99	70.64
XIII	Reserves Excluding Revaluation Reserve as per Balance						
XIV	Paid Up Equity Capital ( Face Value of Rs 10/- Per share )	708.10	708.10	708.10	708.10	708.10	708.10
XVI	Earnings per Equity Share (for continuing operation):						
	(1) Basic	0.22	0.33	0.12	0.99	0.88	0.94
	(2) Diluted	0.22	0.33	0.12	0.99	0.88	0.94

Mumbai  
Date :-14.02.2020



For Sandu Pharmaceuticals Ltd

Umesh Sandu  
Managing Director  
DIN : 01132141

**Regd. & Factory Office:** Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel : +91 832 2407474 / 6715000, Fax : +91 832 2407008, E-mail : sandupharma@sandu.in

CIN:L24233GA1985PLC001587



1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 14<sup>th</sup> February 2020. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 14<sup>th</sup> February, 2020. there are no qualifications in the limited review report issued for the nine months & quarter ended December 2019.
4. Figures for the previous periods have been reclassified/regrouped, whenever necessary

Date: - 14/02/2020



For Sandu Pharmaceuticals Ltd



Umesh Sandu  
Managing Director  
DIN : 01132141





**Dileep & Prithvi**

CHARTERED ACCOUNTANTS

**"LIMITED REVIEW" REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER  
AND NINE MONTHS ENDED ON 31ST DECEMBER, 2019**

To,

**The Board of Directors,  
Sandu Pharmaceuticals Limited,  
Plot No. 25, 26, 29 & 30,  
Pilerne Industrial Estate, Marra,  
Bardez, Goa-403511.**

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and nine months ended on 31<sup>st</sup> Dec, 2019, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Dileep & Prithvi**

Chartered Accountants

Firm Registration Number: 122290W

**Himmat Mali**

(Partner)

Membership Number: 183378

UDIN- **20183378AAAAAR28LS**



Place: Mumbai

Date: 14<sup>th</sup> February, 2020

**HEAD OFFICE :**

4-A, 3rd Floor, Dahanukar Bldg., 480, Kalbadevi Road,  
Mumbai - 400 002. • Tel.: +91-22-22071185 / 40031184  
E-mail : contact@dileepprithvi.com

**BRANCH OFFICE :**

601, Sunshine Building T-39, Opp. Mercedes Auto Hangar,  
Lokhandwala Complex Road, Shastri Nagar, Andheri (W),  
Mumbai - 400 053. • E-mail : prithvi@dileepprithvi.com

**BRANCH OFFICE :**

Office No. 1003-C, 1st Floor, World Trade Centre,  
Near Udhana Darwaja, Ring Road, Surat - 395002. (Gujarat).  
Cell : +91 77679 88047 • E-mail : nikhil@dileepprithvi.com

Web : www.dileepprithvi.com